Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Jill Roberts Center for Inflammatory Bowel Disease
Explore this Website
Home
About Us
Toggle About Us menu options
Clinical Staff
Research Staff
Contact Us
Newsworthy
Toggle Newsworthy menu options
News and Announcements
Patient Care
Toggle Patient Care menu options
Clinical Services
FAQs
For Your Visit
COVID-19 Information
Nutrition Science
Toggle Nutrition Science menu options
Nutrition FAQs
Food Intolerances
News in IBD Nutrition
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Clinical Trials
Publications
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Newsworthy
Patient Care
Nutrition Science
Research and Clinical Trials
Home
Publications
Publications
Clinical Trials
Publications
Publications
Found 61 results
Author
[
Title
]
Type
Year
Filters:
First Letter Of Last Name
is
H
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
V
Narula N
,
Peerani F
,
Meserve J
,
Kochhar G
,
Chaudrey K
,
Hartke J
,
Chilukuri P
,
Koliani-Pace J
,
Winters A
,
Katta L
et al.
. 2018.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
.
Am J Gastroenterol. 113(9):1345.
Narula N
,
Peerani F
,
Meserve J
,
Kochhar G
,
Chaudrey K
,
Hartke J
,
Chilukuri P
,
Koliani-Pace J
,
Winters A
,
Katta L
et al.
. 2018.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
.
Am J Gastroenterol. 113(9):1345.
Narula N
,
Peerani F
,
Meserve J
,
Kochhar G
,
Chaudrey K
,
Hartke J
,
Chilukuri P
,
Koliani-Pace J
,
Winters A
,
Katta L
et al.
. 2018.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
.
Am J Gastroenterol. 113(9):1345.
Hirten R
,
Longman RS
,
Bosworth BP
,
Steinlauf A
,
Scherl E
. 2015.
Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease.
.
Am J Gastroenterol. 110(12):1737-8.
U
Panaccione R
,
Danese S
,
Sandborn WJ
,
O'Brien CD
,
Zhou Y
,
Zhang H
,
Adedokun OJ
,
Tikhonov I
,
Targan S
,
Abreu MT
et al.
. 2020.
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
.
Aliment Pharmacol Ther. 52(11-12):1658-1675.
Qazi T
,
Verma R
,
Hamilton MJ
,
Kaplan ER
,
Redline S
,
Burakoff R
. 2019.
The Use of Actigraphy Differentiates Sleep Disturbances in Active and Inactive Crohn's Disease.
.
Inflamm Bowel Dis. 25(6):1044-1053.
T
Lima S
,
Gogokhia L
,
Viladomiu M
,
Chou L
,
Putzel G
,
Jin W
,
Pires S
,
Guo C-J
,
Gerardin Y
,
Crawford CV
et al.
. 2021.
Transferable Immunoglobulin A-Coated Odoribacter splanchnicus in Responders to Fecal Microbiota Transplantation for Ulcerative Colitis Limits Colonic Inflammation.
.
Gastroenterology.
Zegarra-Ruiz DF
,
Kim DV
,
Norwood K
,
Kim M
,
Wu W-JH
,
Saldana-Morales FB
,
Hill AA
,
Majumdar S
,
Orozco S
,
Bell R
et al.
. 2021.
Thymic development of gut-microbiota-specific T cells.
.
Nature. 594(7863):413-417.
Cohen-Mekelburg S
,
Tafesh Z
,
Coburn E
,
Weg R
,
Malik N
,
Webb C
,
Hammad H
,
Scherl E
,
Bosworth BP
. 2018.
Testing and Treating Small Intestinal Bacterial Overgrowth Reduces Symptoms in Patients with Inflammatory Bowel Disease.
.
Dig Dis Sci. 63(9):2439-2444.
S
Sedano R
,
Hogan M
,
Nguyen TM
,
Chang J
,
Zou GY
,
Macdonald JK
,
Casteele NVande
,
Hanzel J
,
Crowley E
,
Battat R
et al.
. 2021.
Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis.
.
J Crohns Colitis.
Sedano R
,
Hogan M
,
Nguyen TM
,
Chang J
,
Zou GY
,
Macdonald JK
,
Casteele NVande
,
Hanzel J
,
Crowley E
,
Battat R
et al.
. 2021.
Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis.
.
J Crohns Colitis.
Faleck DM
,
Winters A
,
Chablaney S
,
Shashi P
,
Meserve J
,
Weiss A
,
Aniwan S
,
Koliani-Pace JL
,
Kochhar G
,
Boland BS
et al.
. 2019.
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
.
Clin Gastroenterol Hepatol. 17(12):2497-2505.e1.
Faleck DM
,
Winters A
,
Chablaney S
,
Shashi P
,
Meserve J
,
Weiss A
,
Aniwan S
,
Koliani-Pace JL
,
Kochhar G
,
Boland BS
et al.
. 2019.
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
.
Clin Gastroenterol Hepatol. 17(12):2497-2505.e1.
Zhang S
,
Dogan B
,
Guo C
,
Herlekar D
,
Stewart K
,
Scherl EJ
,
Simpson KW
. 2020.
Short Chain Fatty Acids Modulate the Growth and Virulence of Pathosymbiont and Host Response.
.
Antibiotics (Basel). 9(8)
Battat R
,
Duijvestein M
,
Casteele NVande
,
Singh S
,
Dulai PS
,
Valasek MA
,
Mimms L
,
McFarland J
,
Hester KD
,
Renshaw M
et al.
. 2018.
Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease.
.
Clin Gastroenterol Hepatol.
Gu W
,
Wang H
,
Huang X
,
Kraiczy J
,
Singh PNP
,
Ng C
,
Dagdeviren S
,
Houghton S
,
Pellon-Cardenas O
,
Lan Y
et al.
. 2021.
SATB2 preserves colon stem cell identity and mediates ileum-colon conversion via enhancer remodeling.
.
Cell Stem Cell.
Gu W
,
Wang H
,
Huang X
,
Kraiczy J
,
Singh PNP
,
Ng C
,
Dagdeviren S
,
Houghton S
,
Pellon-Cardenas O
,
Lan Y
et al.
. 2021.
SATB2 preserves colon stem cell identity and mediates ileum-colon conversion via enhancer remodeling.
.
Cell Stem Cell.
Gu W
,
Wang H
,
Huang X
,
Kraiczy J
,
Singh PNP
,
Ng C
,
Dagdeviren S
,
Houghton S
,
Pellon-Cardenas O
,
Lan Y
et al.
. 2021.
SATB2 preserves colon stem cell identity and mediates ileum-colon conversion via enhancer remodeling.
.
Cell Stem Cell.
Montrose DC
,
Scherl EJ
,
Bosworth BP
,
Zhou XKathy
,
Jung B
,
Dannenberg AJ
,
Hla T
. 2013.
S1P₁ localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity.
.
J Lipid Res. 54(3):843-51.
R
Cohen-Mekelburg S
,
Schneider Y
,
Gold S
,
Ghosh G
,
Rosenblatt R
,
Hajifathalian K
,
Scherl E
,
Schnoll-Sussman F
,
Katz P
,
Steinlauf A
. 2019.
Risk of Early Colorectal Cancers Needs to Be Considered in Inflammatory Bowel Disease Care.
.
Dig Dis Sci. 64(8):2273-2279.
Kothary V
,
Scherl EJ
,
Bosworth B
,
Jiang Z-D
,
Dupont HL
,
Harel J
,
Simpson KW
,
Dogan B
. 2013.
Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps.
.
Antimicrob Agents Chemother. 57(2):811-7.
Lewis JD
,
Sandler RS
,
Brotherton C
,
Brensinger C
,
Li H
,
Kappelman MD
,
Daniel SG
,
Bittinger K
,
Albenberg L
,
Valentine JF
et al.
. 2021.
A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.
.
Gastroenterology. 161(3):837-852.e9.
Lewis JD
,
Sandler RS
,
Brotherton C
,
Brensinger C
,
Li H
,
Kappelman MD
,
Daniel SG
,
Bittinger K
,
Albenberg L
,
Valentine JF
et al.
. 2021.
A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.
.
Gastroenterology. 161(3):837-852.e9.
Lewis JD
,
Sandler RS
,
Brotherton C
,
Brensinger C
,
Li H
,
Kappelman MD
,
Daniel SG
,
Bittinger K
,
Albenberg L
,
Valentine JF
et al.
. 2021.
A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.
.
Gastroenterology. 161(3):837-852.e9.
P
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
1
(current)
2
3
next ›
last »